Skip to Content

Methyldopa Disease Interactions

There are 8 disease interactions with methyldopa:

Major

Methyldopa (Includes methyldopa) ↔ liver disease

Major Potential Hazard, High plausibility. Applies to: Liver Disease

The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders. Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.

References

  1. Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976): 2001-2
  2. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
  3. Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989): 57-60
  4. Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977): 125-33
  5. Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976): 941-8
  6. Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976): 1602-3
  7. Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977): 579-81
  8. Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985): 1233-9
  9. Sotaniemi EA, Hokkanen OT, Ahokas JT, et al "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977): 429-35
  10. Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982): 41-5
  11. Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978): 572-9
  12. Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973): 177-84
  13. Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976): 144-52
View all 13 references
Moderate

Methyldopa (Includes methyldopa) ↔ cerebrovascular disease

Moderate Potential Hazard, Moderate plausibility. Applies to: History - Cerebrovascular Disease

Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. If these movements occur, therapy should be stopped.

Moderate

Methyldopa (Includes methyldopa) ↔ dialysis

Moderate Potential Hazard, Moderate plausibility. Applies to: hemodialysis

Methyldopa is removed by dialysis. Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.

References

  1. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
  2. Myhre E, Stenbaek O, Rugstad HE, et al "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982): 257-63
  3. Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972): 201-4
  4. Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970): 840-3
View all 4 references
Moderate

Methyldopa (Includes methyldopa) ↔ hemolytic anemia

Moderate Potential Hazard, Low plausibility. Applies to: Anemia, Bleeding

Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs. Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes. Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended. If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued

References

  1. Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977): 1260-1
  2. Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970): 570-3
  3. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
  4. Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981): 54, 58
View all 4 references
Moderate

Methyldopa (Includes methyldopa) ↔ leukopenia

Moderate Potential Hazard, Low plausibility. Applies to: Neutropenia

Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted. White blood cell counts returned to normal with discontinuation of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
Moderate

Methyldopa (Includes methyldopa) ↔ peripheral edema

Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Fluid Retention

Methyldopa may cause edema or weight gain associated with sodium retention. Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.

References

  1. Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988): 700-1
  2. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
Moderate

Methyldopa (Includes methyldopa) ↔ pheochromocytoma

Moderate Potential Hazard, Moderate plausibility. Applies to: Pheochromocytoma

Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported. This will interfere with the diagnosis of pheochromocytoma. It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery. Methyldopa is not recommended for the treatment of patients with pheochromocytoma.

References

  1. Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987): 168-70
  2. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
  3. Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988): 1555-8
Minor

Methyldopa (Includes methyldopa) ↔ psychoses

Minor Potential Hazard, Low plausibility. Applies to: Psychosis

Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy. Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.

References

  1. Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990): 128
  2. Wurzelmann J, Frishman WH, Aronson M, et al "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987): 689-701
  3. "Product Information. Aldomet (methyldopa)." Merck & Co, Inc, West Point, PA.
  4. Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989): 1075-6
  5. Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978): 211-5
View all 5 references

Methyldopa drug interactions

There are 212 drug interactions with methyldopa

Methyldopa alcohol/food interactions

There is 1 alcohol/food interaction with methyldopa

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.